Christopher DeSouza
Concepts (406)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cell-Derived Microparticles | 17 | 2025 | 73 | 10.390 |
Why?
| | Endothelium, Vascular | 47 | 2025 | 922 | 9.720 |
Why?
| | Vasodilation | 31 | 2025 | 494 | 6.710 |
Why?
| | Endothelial Cells | 19 | 2025 | 779 | 6.080 |
Why?
| | Endothelin-1 | 18 | 2025 | 181 | 5.800 |
Why?
| | Vasoconstriction | 14 | 2025 | 202 | 4.030 |
Why?
| | Fibrinolysis | 16 | 2023 | 143 | 3.340 |
Why?
| | Human Umbilical Vein Endothelial Cells | 8 | 2025 | 104 | 3.060 |
Why?
| | Tissue Plasminogen Activator | 18 | 2024 | 225 | 2.970 |
Why?
| | Nitric Oxide | 15 | 2025 | 914 | 2.950 |
Why?
| | Vasodilator Agents | 23 | 2025 | 333 | 2.910 |
Why?
| | Forearm | 19 | 2025 | 120 | 2.860 |
Why?
| | Spinal Cord Injuries | 5 | 2025 | 209 | 2.680 |
Why?
| | Hypertension | 14 | 2023 | 1291 | 2.680 |
Why?
| | Sleep Deprivation | 6 | 2021 | 174 | 2.630 |
Why?
| | Aging | 40 | 2025 | 1863 | 2.600 |
Why?
| | Obesity | 20 | 2025 | 2966 | 2.520 |
Why?
| | Nitric Oxide Synthase Type III | 9 | 2025 | 203 | 2.300 |
Why?
| | Overweight | 9 | 2018 | 554 | 2.140 |
Why?
| | MicroRNAs | 7 | 2025 | 703 | 2.130 |
Why?
| | Acetylcholine | 18 | 2025 | 186 | 2.030 |
Why?
| | Exercise | 34 | 2024 | 2015 | 1.820 |
Why?
| | Middle Aged | 113 | 2025 | 33118 | 1.760 |
Why?
| | Prehypertension | 5 | 2015 | 28 | 1.700 |
Why?
| | Regional Blood Flow | 24 | 2025 | 474 | 1.700 |
Why?
| | Apoptosis | 16 | 2025 | 2542 | 1.670 |
Why?
| | Vasomotor System | 2 | 2025 | 46 | 1.610 |
Why?
| | Blood Pressure | 20 | 2021 | 1774 | 1.540 |
Why?
| | Cardiovascular Diseases | 11 | 2021 | 2110 | 1.530 |
Why?
| | HIV Envelope Protein gp120 | 3 | 2019 | 60 | 1.520 |
Why?
| | Sleep | 5 | 2021 | 751 | 1.430 |
Why?
| | Polycythemia | 2 | 2021 | 21 | 1.430 |
Why?
| | Stem Cells | 8 | 2012 | 589 | 1.400 |
Why?
| | Postmenopause | 18 | 2023 | 361 | 1.260 |
Why?
| | NG-Nitroarginine Methyl Ester | 3 | 2024 | 48 | 1.240 |
Why?
| | Nitroprusside | 16 | 2021 | 69 | 1.230 |
Why?
| | Male | 94 | 2025 | 67308 | 1.220 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 24 | 1.200 |
Why?
| | Enzyme Inhibitors | 6 | 2024 | 845 | 1.200 |
Why?
| | Circulating MicroRNA | 2 | 2019 | 25 | 1.170 |
Why?
| | C-Reactive Protein | 7 | 2015 | 409 | 1.160 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 348 | 1.150 |
Why?
| | Humans | 140 | 2025 | 136899 | 1.100 |
Why?
| | Nebivolol | 2 | 2017 | 9 | 1.080 |
Why?
| | Cell Movement | 8 | 2014 | 971 | 1.070 |
Why?
| | Atherosclerosis | 2 | 2023 | 411 | 1.060 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 53 | 1.020 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 260 | 1.020 |
Why?
| | Caspase 3 | 5 | 2017 | 246 | 1.000 |
Why?
| | Adult | 70 | 2025 | 37595 | 0.980 |
Why?
| | Erythritol | 1 | 2025 | 2 | 0.970 |
Why?
| | Inflammation Mediators | 5 | 2024 | 514 | 0.960 |
Why?
| | Microvessels | 2 | 2025 | 86 | 0.930 |
Why?
| | Sweetening Agents | 1 | 2025 | 53 | 0.920 |
Why?
| | Female | 84 | 2025 | 72703 | 0.910 |
Why?
| | Vasoconstrictor Agents | 6 | 2023 | 137 | 0.900 |
Why?
| | Aged | 66 | 2025 | 23641 | 0.890 |
Why?
| | Work-Life Balance | 1 | 2024 | 19 | 0.890 |
Why?
| | Cells, Cultured | 10 | 2025 | 4204 | 0.890 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2023 | 84 | 0.860 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 146 | 0.820 |
Why?
| | Physical Endurance | 16 | 2024 | 274 | 0.810 |
Why?
| | Goals | 1 | 2024 | 168 | 0.800 |
Why?
| | Dietary Fats | 2 | 2015 | 301 | 0.790 |
Why?
| | Oxidative Stress | 8 | 2025 | 1302 | 0.780 |
Why?
| | Blood Coagulation | 2 | 2021 | 254 | 0.750 |
Why?
| | Estrogen Replacement Therapy | 9 | 2003 | 146 | 0.710 |
Why?
| | Vascular Diseases | 1 | 2023 | 244 | 0.700 |
Why?
| | Biomarkers | 13 | 2025 | 4148 | 0.680 |
Why?
| | Altitude | 3 | 2021 | 479 | 0.670 |
Why?
| | Physical Fitness | 12 | 2005 | 208 | 0.640 |
Why?
| | Case-Control Studies | 11 | 2021 | 3528 | 0.640 |
Why?
| | Ascorbic Acid | 3 | 2021 | 123 | 0.630 |
Why?
| | Acclimatization | 1 | 2021 | 173 | 0.630 |
Why?
| | Hemodynamics | 8 | 2021 | 1114 | 0.620 |
Why?
| | Cross-Sectional Studies | 23 | 2023 | 5398 | 0.620 |
Why?
| | Endothelium | 3 | 2020 | 122 | 0.590 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 425 | 0.590 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2017 | 2066 | 0.590 |
Why?
| | Telomere | 3 | 2010 | 280 | 0.580 |
Why?
| | Metoprolol | 1 | 2017 | 40 | 0.560 |
Why?
| | HIV | 1 | 2019 | 232 | 0.560 |
Why?
| | Hematopoietic Stem Cells | 2 | 2011 | 398 | 0.560 |
Why?
| | Plethysmography | 5 | 2017 | 106 | 0.550 |
Why?
| | Blood Glucose | 7 | 2019 | 2161 | 0.550 |
Why?
| | Hyperglycemia | 2 | 2018 | 344 | 0.540 |
Why?
| | Bradykinin | 8 | 2015 | 46 | 0.530 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 64 | 0.530 |
Why?
| | HIV Infections | 4 | 2019 | 2822 | 0.520 |
Why?
| | Plasminogen Activator Inhibitor 1 | 7 | 2023 | 86 | 0.520 |
Why?
| | Stress, Physiological | 2 | 2017 | 444 | 0.510 |
Why?
| | Cytokines | 4 | 2020 | 2078 | 0.510 |
Why?
| | Cellular Senescence | 1 | 2018 | 188 | 0.500 |
Why?
| | Body Mass Index | 15 | 2017 | 2351 | 0.500 |
Why?
| | Young Adult | 13 | 2025 | 13157 | 0.490 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 241 | 0.480 |
Why?
| | Interleukin-6 | 6 | 2025 | 771 | 0.470 |
Why?
| | Gender Identity | 2 | 2006 | 124 | 0.470 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 156 | 0.460 |
Why?
| | Reactive Oxygen Species | 3 | 2025 | 619 | 0.460 |
Why?
| | Diet, High-Fat | 2 | 2018 | 248 | 0.450 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 20 | 0.430 |
Why?
| | Interleukin-8 | 3 | 2025 | 269 | 0.430 |
Why?
| | Blood Platelets | 1 | 2017 | 405 | 0.420 |
Why?
| | Analysis of Variance | 7 | 2016 | 1324 | 0.420 |
Why?
| | Glucose | 2 | 2017 | 1018 | 0.420 |
Why?
| | Brain | 2 | 2025 | 2828 | 0.410 |
Why?
| | Adiposity | 3 | 2016 | 517 | 0.410 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 59 | 0.400 |
Why?
| | Colony-Forming Units Assay | 6 | 2014 | 91 | 0.400 |
Why?
| | Transcription Factor RelA | 2 | 2024 | 86 | 0.400 |
Why?
| | Blood Vessels | 1 | 2014 | 187 | 0.390 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 25 | 0.390 |
Why?
| | Arteries | 7 | 2018 | 269 | 0.390 |
Why?
| | Alkalosis, Respiratory | 2 | 2023 | 2 | 0.390 |
Why?
| | Inflammation | 5 | 2025 | 2817 | 0.390 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 773 | 0.380 |
Why?
| | Coronary Disease | 3 | 2007 | 385 | 0.380 |
Why?
| | Oxygen Consumption | 12 | 2024 | 681 | 0.380 |
Why?
| | Body Composition | 14 | 2009 | 665 | 0.380 |
Why?
| | Glucose Intolerance | 1 | 2013 | 146 | 0.370 |
Why?
| | T-Lymphocytes | 2 | 2010 | 1996 | 0.360 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2010 | 446 | 0.360 |
Why?
| | NF-kappa B | 3 | 2025 | 685 | 0.360 |
Why?
| | Time Factors | 10 | 2021 | 6802 | 0.360 |
Why?
| | Abdominal Fat | 1 | 2011 | 40 | 0.360 |
Why?
| | Age Factors | 9 | 2025 | 3290 | 0.350 |
Why?
| | Fatty Acids | 1 | 2014 | 443 | 0.350 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.350 |
Why?
| | Muscle Tonus | 2 | 2010 | 21 | 0.350 |
Why?
| | HIV Protease Inhibitors | 1 | 2011 | 69 | 0.340 |
Why?
| | Risk Factors | 14 | 2018 | 10313 | 0.340 |
Why?
| | Dyslipidemias | 1 | 2012 | 177 | 0.330 |
Why?
| | Chemotaxis | 1 | 2010 | 131 | 0.330 |
Why?
| | HIV-1 | 2 | 2019 | 862 | 0.330 |
Why?
| | Health | 1 | 2010 | 84 | 0.320 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 362 | 0.320 |
Why?
| | Postprandial Period | 3 | 2019 | 105 | 0.320 |
Why?
| | Heart Failure | 1 | 2023 | 2210 | 0.320 |
Why?
| | Disease | 1 | 2010 | 98 | 0.310 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 283 | 0.310 |
Why?
| | Feeding Behavior | 1 | 2015 | 648 | 0.310 |
Why?
| | Flow Cytometry | 4 | 2019 | 1185 | 0.310 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 543 | 0.300 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 16 | 0.290 |
Why?
| | Phosphorylation | 2 | 2024 | 1762 | 0.290 |
Why?
| | Fasting | 4 | 2019 | 276 | 0.280 |
Why?
| | Reference Values | 7 | 2016 | 820 | 0.270 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 27 | 0.270 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 62 | 0.270 |
Why?
| | Exercise Therapy | 4 | 2017 | 432 | 0.270 |
Why?
| | Adult Stem Cells | 1 | 2006 | 41 | 0.260 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 5 | 0.240 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 658 | 0.240 |
Why?
| | Double-Blind Method | 5 | 2021 | 1980 | 0.240 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 263 | 0.230 |
Why?
| | Hyperthermia, Induced | 2 | 2023 | 114 | 0.230 |
Why?
| | Walking | 5 | 2018 | 514 | 0.230 |
Why?
| | Premenopause | 5 | 2002 | 125 | 0.220 |
Why?
| | Adipose Tissue | 6 | 2005 | 624 | 0.220 |
Why?
| | Physiology | 1 | 2024 | 15 | 0.220 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 141 | 0.220 |
Why?
| | Blood Flow Velocity | 3 | 2012 | 412 | 0.220 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.220 |
Why?
| | Quadriplegia | 1 | 2023 | 12 | 0.220 |
Why?
| | Signal Transduction | 5 | 2025 | 5077 | 0.220 |
Why?
| | Antihypertensive Agents | 4 | 2013 | 493 | 0.210 |
Why?
| | Carotid Arteries | 5 | 2003 | 206 | 0.210 |
Why?
| | Hypertrophy | 2 | 2023 | 133 | 0.210 |
Why?
| | von Willebrand Factor | 1 | 2023 | 80 | 0.210 |
Why?
| | Actinin | 1 | 2023 | 13 | 0.210 |
Why?
| | Thrombophilia | 1 | 2023 | 85 | 0.210 |
Why?
| | Running | 5 | 2000 | 198 | 0.200 |
Why?
| | Troponin T | 1 | 2023 | 67 | 0.200 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 43 | 0.190 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 50 | 0.190 |
Why?
| | Career Choice | 1 | 2024 | 215 | 0.190 |
Why?
| | Vaping | 1 | 2023 | 63 | 0.190 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.180 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 109 | 0.180 |
Why?
| | Respiratory Muscles | 1 | 2021 | 33 | 0.180 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.180 |
Why?
| | Colorado | 6 | 2024 | 4491 | 0.180 |
Why?
| | Sex Characteristics | 4 | 2017 | 766 | 0.180 |
Why?
| | Diet, Sodium-Restricted | 1 | 2001 | 36 | 0.180 |
Why?
| | South America | 1 | 2021 | 59 | 0.180 |
Why?
| | Estradiol | 1 | 2025 | 513 | 0.180 |
Why?
| | Peru | 1 | 2021 | 59 | 0.180 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2018 | 37 | 0.170 |
Why?
| | Lymphocyte Count | 2 | 2011 | 150 | 0.170 |
Why?
| | Endothelins | 1 | 2021 | 64 | 0.170 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 34 | 0.170 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 784 | 0.170 |
Why?
| | Cytochromes c | 2 | 2010 | 60 | 0.170 |
Why?
| | Fibrosis | 1 | 2023 | 552 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2015 | 1242 | 0.170 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 480 | 0.170 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 80 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2019 | 2508 | 0.160 |
Why?
| | Fibrinogen | 2 | 1998 | 170 | 0.160 |
Why?
| | Piperidines | 2 | 2013 | 207 | 0.160 |
Why?
| | Oligopeptides | 2 | 2013 | 273 | 0.160 |
Why?
| | Physical Exertion | 2 | 1998 | 212 | 0.160 |
Why?
| | Fever | 2 | 2020 | 307 | 0.160 |
Why?
| | Insulin Glargine | 1 | 2019 | 84 | 0.150 |
Why?
| | Chronic Disease | 1 | 2025 | 1773 | 0.150 |
Why?
| | Cell Proliferation | 1 | 2006 | 2471 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 219 | 0.150 |
Why?
| | E-Selectin | 1 | 2018 | 58 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 356 | 0.150 |
Why?
| | HIV Antibodies | 1 | 2019 | 62 | 0.150 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 411 | 0.150 |
Why?
| | Myocytes, Cardiac | 1 | 2023 | 526 | 0.150 |
Why?
| | Brachial Artery | 3 | 2017 | 200 | 0.150 |
Why?
| | Telomerase | 2 | 2011 | 250 | 0.150 |
Why?
| | Phenotype | 2 | 2021 | 3201 | 0.150 |
Why?
| | Heat-Shock Response | 1 | 2018 | 78 | 0.140 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2017 | 11 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5126 | 0.140 |
Why?
| | Antioxidants | 1 | 2021 | 577 | 0.140 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 39 | 0.140 |
Why?
| | Myocardial Infarction | 1 | 2005 | 1044 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 688 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2018 | 153 | 0.140 |
Why?
| | Pilot Projects | 1 | 2023 | 1684 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2021 | 10768 | 0.140 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 139 | 0.140 |
Why?
| | Heart | 1 | 2021 | 660 | 0.130 |
Why?
| | Lipids | 3 | 2009 | 664 | 0.130 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 17 | 0.130 |
Why?
| | Prognosis | 3 | 2018 | 4011 | 0.130 |
Why?
| | Anthropometry | 2 | 2011 | 214 | 0.130 |
Why?
| | Enzyme Activation | 1 | 2017 | 816 | 0.120 |
Why?
| | Triglycerides | 3 | 2005 | 524 | 0.120 |
Why?
| | Baroreflex | 3 | 2001 | 57 | 0.120 |
Why?
| | Insulin | 2 | 2005 | 2389 | 0.120 |
Why?
| | Substance P | 2 | 2008 | 43 | 0.120 |
Why?
| | Isoproterenol | 2 | 2008 | 116 | 0.120 |
Why?
| | Blood Circulation | 1 | 2015 | 41 | 0.120 |
Why?
| | Down-Regulation | 1 | 2017 | 658 | 0.120 |
Why?
| | Insulin Resistance | 2 | 2003 | 1187 | 0.120 |
Why?
| | Interleukin-18 | 2 | 2006 | 237 | 0.110 |
Why?
| | Hot Temperature | 1 | 2017 | 407 | 0.110 |
Why?
| | Cross-Over Studies | 4 | 2017 | 561 | 0.110 |
Why?
| | Peptides | 1 | 2019 | 981 | 0.110 |
Why?
| | Regression Analysis | 5 | 2011 | 1026 | 0.110 |
Why?
| | Physical Education and Training | 2 | 2024 | 75 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 302 | 0.100 |
Why?
| | Hydrocortisone | 1 | 2015 | 317 | 0.100 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 6 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 208 | 0.090 |
Why?
| | Blood Volume | 4 | 1999 | 61 | 0.090 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 48 | 0.090 |
Why?
| | Waist Circumference | 1 | 2011 | 143 | 0.090 |
Why?
| | Circadian Rhythm | 1 | 2015 | 463 | 0.090 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 57 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1282 | 0.090 |
Why?
| | Femoral Artery | 2 | 2002 | 178 | 0.080 |
Why?
| | Vital Capacity | 2 | 2002 | 309 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 188 | 0.080 |
Why?
| | Prevalence | 3 | 2014 | 2709 | 0.080 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.080 |
Why?
| | Staurosporine | 1 | 2010 | 20 | 0.080 |
Why?
| | Estrogens | 2 | 2003 | 358 | 0.080 |
Why?
| | Cholesterol | 2 | 2005 | 412 | 0.080 |
Why?
| | Cerebrovascular Circulation | 2 | 2023 | 241 | 0.080 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 74 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 62 | 0.080 |
Why?
| | Leg | 2 | 2001 | 223 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2003 | 7552 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 219 | 0.080 |
Why?
| | CD3 Complex | 1 | 2009 | 106 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 319 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 366 | 0.080 |
Why?
| | Life Style | 5 | 2003 | 480 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 212 | 0.080 |
Why?
| | Up-Regulation | 1 | 2012 | 846 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 437 | 0.080 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.070 |
Why?
| | Adolescent | 6 | 2025 | 21402 | 0.070 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 29 | 0.070 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 62 | 0.070 |
Why?
| | Methacholine Chloride | 1 | 2008 | 52 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 321 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 168 | 0.070 |
Why?
| | Hemiplegia | 2 | 1997 | 21 | 0.070 |
Why?
| | Arm | 1 | 2007 | 106 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2007 | 141 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 3432 | 0.060 |
Why?
| | Probability | 1 | 2007 | 311 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 119 | 0.060 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2005 | 18 | 0.060 |
Why?
| | Thymidine | 1 | 2005 | 60 | 0.060 |
Why?
| | Muscle, Skeletal | 3 | 2002 | 1699 | 0.060 |
Why?
| | DNA Methylation | 1 | 2010 | 644 | 0.060 |
Why?
| | Weight Loss | 1 | 2010 | 765 | 0.060 |
Why?
| | Bone Marrow Cells | 1 | 2005 | 313 | 0.060 |
Why?
| | Anaerobic Threshold | 2 | 2005 | 28 | 0.050 |
Why?
| | France | 1 | 2024 | 33 | 0.050 |
Why?
| | Hypocapnia | 1 | 2023 | 8 | 0.050 |
Why?
| | Hyperventilation | 1 | 2023 | 10 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 438 | 0.050 |
Why?
| | Thrombosis | 1 | 2007 | 368 | 0.050 |
Why?
| | Adenine | 1 | 2005 | 267 | 0.050 |
Why?
| | History, 21st Century | 1 | 2024 | 211 | 0.050 |
Why?
| | Compliance | 4 | 2008 | 47 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 973 | 0.050 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 28 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 29 | 0.050 |
Why?
| | History, 20th Century | 1 | 2024 | 324 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1059 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 39 | 0.050 |
Why?
| | Bicycling | 1 | 2024 | 116 | 0.050 |
Why?
| | Heart Rate | 4 | 2001 | 830 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1945 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 652 | 0.050 |
Why?
| | Exercise Test | 3 | 2005 | 621 | 0.050 |
Why?
| | Carotid Artery Diseases | 1 | 2002 | 66 | 0.050 |
Why?
| | Progesterone | 1 | 2003 | 251 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 133 | 0.050 |
Why?
| | Universities | 1 | 2024 | 431 | 0.050 |
Why?
| | Tunica Intima | 4 | 2002 | 84 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 267 | 0.050 |
Why?
| | Systole | 1 | 2001 | 191 | 0.040 |
Why?
| | Heart Conduction System | 1 | 2001 | 100 | 0.040 |
Why?
| | Ultrasonography | 5 | 2002 | 749 | 0.040 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2000 | 43 | 0.040 |
Why?
| | Mexican Americans | 1 | 2001 | 117 | 0.040 |
Why?
| | Knee | 1 | 2000 | 67 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2030 | 0.040 |
Why?
| | Hemorheology | 1 | 2018 | 22 | 0.040 |
Why?
| | Oxygen | 1 | 2024 | 943 | 0.040 |
Why?
| | Energy Intake | 2 | 1998 | 473 | 0.040 |
Why?
| | Body Constitution | 1 | 1998 | 55 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 339 | 0.040 |
Why?
| | Social Class | 1 | 2001 | 277 | 0.040 |
Why?
| | Diet, Fat-Restricted | 1 | 2018 | 79 | 0.040 |
Why?
| | Hemostasis | 1 | 1998 | 82 | 0.040 |
Why?
| | Plasminogen Activators | 1 | 1997 | 7 | 0.030 |
Why?
| | Cervical Vertebrae | 1 | 2018 | 135 | 0.030 |
Why?
| | Gait | 2 | 1997 | 279 | 0.030 |
Why?
| | Vascular Resistance | 1 | 1998 | 372 | 0.030 |
Why?
| | United States | 1 | 2014 | 14595 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 5711 | 0.030 |
Why?
| | Movement Disorders | 1 | 1997 | 59 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 1997 | 96 | 0.030 |
Why?
| | Chromium | 1 | 1996 | 14 | 0.030 |
Why?
| | Weight Lifting | 1 | 1996 | 34 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 557 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2615 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2655 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1240 | 0.030 |
Why?
| | Hypoxia | 1 | 2021 | 1106 | 0.030 |
Why?
| | Antigens | 1 | 1996 | 358 | 0.030 |
Why?
| | Swimming | 3 | 1999 | 50 | 0.030 |
Why?
| | Menopause | 1 | 1997 | 315 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 152 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1460 | 0.030 |
Why?
| | Defibrillators, Implantable | 1 | 1997 | 311 | 0.030 |
Why?
| | Brain Ischemia | 1 | 1997 | 341 | 0.030 |
Why?
| | Tunica Media | 2 | 2001 | 38 | 0.020 |
Why?
| | Sex Factors | 1 | 1996 | 2067 | 0.020 |
Why?
| | Animals | 3 | 2024 | 36915 | 0.020 |
Why?
| | Cardiac Output | 2 | 1998 | 164 | 0.020 |
Why?
| | Prospective Studies | 4 | 2001 | 7543 | 0.020 |
Why?
| | Bone Density | 1 | 2010 | 486 | 0.020 |
Why?
| | Stroke Volume | 2 | 1998 | 611 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 52 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 92 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 159 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 166 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2002 | 251 | 0.010 |
Why?
| | Blood Viscosity | 1 | 2001 | 16 | 0.010 |
Why?
| | Habits | 1 | 2001 | 46 | 0.010 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.010 |
Why?
| | Thigh | 1 | 2000 | 52 | 0.010 |
Why?
| | Thinness | 1 | 2000 | 91 | 0.010 |
Why?
| | Mexico | 1 | 2001 | 220 | 0.010 |
Why?
| | Elasticity | 1 | 2000 | 195 | 0.010 |
Why?
| | Erythrocyte Volume | 1 | 1999 | 6 | 0.010 |
Why?
| | Plasma Volume | 1 | 1999 | 19 | 0.010 |
Why?
| | Femur | 1 | 2001 | 259 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2001 | 475 | 0.010 |
Why?
| | Supine Position | 1 | 1998 | 39 | 0.010 |
Why?
| | Posture | 1 | 1999 | 181 | 0.010 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 148 | 0.010 |
Why?
| | Hematocrit | 1 | 1997 | 95 | 0.010 |
Why?
| | Rest | 1 | 1997 | 122 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1997 | 95 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1279 | 0.010 |
Why?
| | Ventricular Fibrillation | 1 | 1997 | 60 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1997 | 112 | 0.010 |
Why?
| | Hyperlipidemias | 1 | 1997 | 120 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1997 | 226 | 0.010 |
Why?
| | Equipment Design | 1 | 1997 | 523 | 0.010 |
Why?
| | Tachycardia, Ventricular | 1 | 1997 | 174 | 0.010 |
Why?
| | Electrocardiography | 1 | 1998 | 632 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1998 | 1524 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1679 | 0.010 |
Why?
| | Stroke | 1 | 2002 | 1122 | 0.010 |
Why?
| | Heart Arrest | 1 | 1997 | 335 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1972 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1997 | 892 | 0.010 |
Why?
| | Length of Stay | 1 | 1997 | 1203 | 0.010 |
Why?
| | Smoking | 1 | 1997 | 1633 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2003 | 15514 | 0.000 |
Why?
|
|
DeSouza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|